# Phathom Pharmaceuticals, Inc.

**PHAT**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001783183


# None

**No letter**

6 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $259.1M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data<br>not computable: distress |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Feb 26, 2026<br>248 days before the rescan; latest periodic filing 10-Q received Oct 29, 2026 |
| **Last close** | $5.73<br>2026-10-30; market equity $465.8M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 26, 2026*

We are a commercial-stage biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal, or GI, diseases. Our approved products, VOQUEZNA®, VOQUEZNA® DUAL PAK® and VOQUEZNA® TRIPLE PAK®, contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB. PCABs are a novel class of molecules that block acid secretion in the stomach. VOQUEZNA is the only PCAB currently approved for marketing and sale in the United States. We began U.S. commercialization of VOQUEZNA for the treatment of erosive gastroesophageal reflux disease, or Erosive GERD, and Helicobacter pylori, or H.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 21.5** | | | | | | |
| Gross profitability | 58.9% | 32.4% | | 17.5 | 366 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *average invested capital must exceed $1,000,000* | | | | | |
| Accruals ratio | (17.1%) | (6.6%) | 25.4 | 803 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 3* | | | | | |
| **Solvency, sleeve percentile 75.3** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | (21.03) | (0.35) | 74.7 | 748 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *EBITDA must exceed $100,000* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 1.73x | 2.92x | 76.0 | 829 | 2025-12-31 |
| **Growth and financing, sleeve percentile 40.1** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 3* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *NOPAT must exceed $100,000* | | | | | |
| Asset growth, three years | 16.3% | 2.2% | 25.3 | 696 | 2025-12-31 |
| Net share issuance, one year | 13.2% | 2.5% | 54.9 | 631 | 2026-02-23 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (46.1%) | (2.2%) | 18 |
| Distance from 52-week high | (68.3%) | (28.7%) | 15 |
| EBIT to enterprise value | (35.7%) | (1.4%) | 17 |
| Free cash flow yield | (35.8%) | (1.0%) | 17 |
| Book value to price | (0.75) | 0.28 | 2 |
| Sales to price | 0.38 | 0.30 | 57 |
| Composite equity issuance, five years | 95.4% | 20.5% | 76 |
| Relative strength against the sector, log excess return | (0.79) | (0.19) | 18 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 4 of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Asset turnover improved | pass |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $184.6M |
| Operating cash flow, four quarters | -$20.7M |
| Months of runway | 106.8 |
| Days since last periodic filing | 3 (10-Q received Oct 29, 2026) |
| Median daily dollar volume, 63 sessions | $10.1M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $152.5M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 2 | assets | us-gaap:Assets | $259.1M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | -$160.0M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$221.2M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 6 | total debt | us-gaap:LongTermDebt | $209.1M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 7 | book equity | us-gaap:StockholdersEquity | -$438.2M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $130.0M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 9 | total debt | us-gaap:LongTermDebt | $201.4M | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 10 | book equity | us-gaap:StockholdersEquity | -$253.6M | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $297.3M | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 12 | net income | us-gaap:NetIncomeLoss | -$221.2M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$166.8M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 14 | assets | us-gaap:Assets | $378.3M | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 15 | current assets | us-gaap:AssetsCurrent | $229.0M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $132.0M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.5B | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 18 | liabilities | us-gaap:Liabilities | $697.3M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 19 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $633,000 | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 20 | operating income | us-gaap:OperatingIncomeLoss | -$167.3M | 2023-12-31 | 2025-03-06 | 10-K | 25-034183 |
| 21 | interest expense | us-gaap:InterestExpense | $42.0M | 2023-12-31 | 2024-06-14 | 10-K/A | 24-073629 |
| 22 | revenue | us-gaap:Revenues | $175.1M | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 23 | revenue | us-gaap:Revenues | $55.3M | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 24 | revenue | us-gaap:Revenues | $682,000 | 2023-12-31 | 2025-03-06 | 10-K | 25-034183 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $229,000 | 2025-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$266.8M | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $135,000 | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$137.6M | 2023-12-31 | 2025-03-06 | 10-K | 25-034183 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.6M | 2023-12-31 | 2025-03-06 | 10-K | 25-034183 |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$146.5M | 2022-12-31 | 2024-06-14 | 10-K/A | 24-073629 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.0M | 2022-12-31 | 2024-06-14 | 10-K/A | 24-073629 |
| 32 | current assets | us-gaap:AssetsCurrent | $360.1M | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 33 | current liabilities | us-gaap:LiabilitiesCurrent | $85.7M | 2024-12-31 | 2026-02-26 | 10-K | 26-073379 |
| 34 | assets | us-gaap:Assets | $413.8M | 2023-12-31 | 2025-03-06 | 10-K | 25-034183 |
| 35 | assets | us-gaap:Assets | $164.8M | 2022-12-31 | 2024-06-14 | 10-K/A | 24-073629 |
| 36 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 78,798,712 | 2026-02-23 | 2026-02-26 | 10-K | 26-073379 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 69,636,970 | 2025-03-03 | 2025-03-06 | 10-K | 25-034183 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.